Literature DB >> 29663522

Tricuspid valve endocarditis in the era of the opioid epidemic.

Tyler J Wallen1,2, Wilson Szeto2, Matthew Williams2, Pavan Atluri2, George Arnaoutakis3, Marci Fults1, Ibrahim Sultan4, Nimesh Desai2, Michael Acker2, Prashanth Vallabhajosyula2.   

Abstract

BACKGROUND AND AIM: We reviewed our institutional experience with tricuspid valve endocarditis to understand the impact of the opioid epidemic on the incidence of right heart endocarditis.
METHODS: We retrospectively reviewed all cases of tricuspid endocarditis managed surgically from January of 2011 to May of 2017. There were no exclusion criteria.
RESULTS: A total of 126 patients were identified. There were seven cases in 2011 and 36 in 2016. The average age of the patients decreased from 52.85 ± 19.6 years in 2011 to 39.2 ± 12.9 in 2017. Caucasians comprised 71% of the patients in 2011 and 75% in 2016. Tricuspid valve replacement was performed in 74 patients (58.73%) and repair was performed in 52 (41.27%). Thirty-day mortality was 11.11%. Reoperation, stroke and renal failure requiring dialysis during the index hospitalization were 5.6%, 0.8%, and 8%, respectively. Staphylococcus aureus, found in 43% of cases, was the most common isolate throughout the study period. Streptococcus was the second most common causative agent.
CONCLUSIONS: In a span of 5 years, our institution has noted a fivefold increase in surgical volume for tricuspid endocarditis, most likely related to the impact of the opioid epidemic.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiovascular research; endocarditis; opioid; valve repair/replacement

Mesh:

Year:  2018        PMID: 29663522     DOI: 10.1111/jocs.13600

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  5 in total

1.  Tricuspid Valve Leaflet Repair and Augmentation for Infective Endocarditis.

Authors:  Alexander A Brescia; Tessa M F Watt; Aaron M Williams; Matthew A Romano; Steven F Bolling
Journal:  Oper Tech Thorac Cardiovasc Surg       Date:  2019-10-25

2.  Heart failure presentation thirty years after tricuspid valvectomy for infective endocarditis.

Authors:  Michael P Rogers; Christopher Bitetzakis; Aarti Patel; Robert L Hooker
Journal:  JTCVS Tech       Date:  2022-01-20

3.  Permanent pacemaker placement following valve surgery is not independently associated with worse outcomes.

Authors:  Valentino Bianco; Arman Kilic; Edgar Aranda-Michel; Derek Serna-Gallegos; Courtenay Dunn-Lewis; Shangzhen Chen; Floyd Thoma; Forozan Navid; Ibrahim Sultan
Journal:  JTCVS Open       Date:  2021-06-16

4.  Optimum surgical treatment for tricuspid valve infective endocarditis: An analysis of the Society of Thoracic Surgeons national database.

Authors:  Mark S Slaughter; Vinay Badhwar; Mickey Ising; Brian L Ganzel; Kristen Sell-Dottin; Oliver K Jawitz; Shuaiqi Zhang; Jaimin R Trivedi
Journal:  J Thorac Cardiovasc Surg       Date:  2019-11-11       Impact factor: 5.209

5.  Clinical Characteristics and Factors Associated With Mortality in First-Episode Infective Endocarditis Among Persons Who Inject Drugs.

Authors:  Laura Rodger; Stephannie Dresden Glockler-Lauf; Esfandiar Shojaei; Adeel Sherazi; Brian Hallam; Sharon Koivu; Kaveri Gupta; Seyed M Hosseini-Moghaddam; Michael Silverman
Journal:  JAMA Netw Open       Date:  2018-11-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.